AGC, a Tokyo-headquartered manufacturer of glass and chemicals, is planning an expansion of its facilities in Chiba, Japan to increase the company’s manufacturing capacity for pharmaceutical intermediates and active pharmaceutical ingredients (APIs).

The new capacity, which will increase capacity at the Chiba plant by tenfold, is set to come on line in October 2019. While AGC previously mainly provided contract services for the development stage of new drugs, this expansion will give AGC the end-to-end capability to produce commercial drugs too. The new facilities will also be capable of producing highly potent APIs.  

AGC began developing and manufacturing pharmaceutical and agrochemical intermediates and active ingredients on a contract basis in the 1980s.

Source: AGC